Rapamycin

mTORC1 Inhibition — The Core Lever#

Rapamycin enters cells and binds the immunophilin FKBP12. That complex then docks onto the FRB domain of mTOR and allosterically shuts down mTOR Complex 1 (mTORC1) — the kinase hub that integrates nutrient status (amino acids, especially leucine), growth-factor signalling (IGF-1, insulin), and cellular energy (ATP) into downstream decisions about whether to build or recycle.

When mTORC1 goes quiet, its two main substrates — S6K1 and 4E-BP1 — stop driving cap-dependent translation. Protein synthesis, ribosome biogenesis, and lipogenesis all dial down. In aging research, this state mimics the molecular signature of caloric restriction, which is exactly why a once-weekly pulse is the longevity dose: you get a transient "fasting-like" signal without actually fasting.

"Rapamycin, an inhibitor of the mTOR pathway, robustly increased both median and maximum lifespan in male and female mice, even when started late in life." — Harrison DE, Strong R, Sharp ZD, et al. Nature, 2009

For the reader: this is also why rapamycin dosing is not recommended within 48–72 hours of a heavy training session. The same mTORC1 signal that rapamycin suppresses is the one that converts a hypertrophy stimulus into new muscle protein. Schedule it on a rest day, well away from your hardest lift.

Autophagy — Why Weekly Pulses Matter#

mTORC1 is the master brake on autophagy, the cellular process of tagging damaged proteins, misfolded aggregates, and dysfunctional mitochondria for lysosomal recycling. Inhibit mTORC1, and autophagy flux increases within hours.

This is the mechanism behind most of rapamycin's aging claims: clearance of senescent-cell products, reduction in proteotoxic stress, improved mitochondrial quality control, and dampening of the senescence-associated secretory phenotype (SASP) — the inflammatory cytokine cocktail that senescent cells pump into surrounding tissue.

For physique-focused users coming off heavy orals or a long blast, an 8-week weekly rapamycin pulse is essentially a structured autophagy phase — the cellular equivalent of a deload.

mTORC2 Preservation — The Reason for Weekly Dosing#

There are two mTOR complexes. mTORC1 is rapamycin-sensitive acutely. mTORC2 — which runs Akt, PKC, and insulin sensitivity — is not directly inhibited by a single dose. But if you dose rapamycin daily (transplant-style), the drug sequesters newly synthesized mTOR protein before it can assemble into mTORC2, and you progressively hollow out the complex. That's what produces the glucose intolerance, hyperlipidemia, and impaired wound healing seen in transplant patients.

"Chronic rapamycin treatment impaired glucose tolerance and insulin sensitivity through disruption of mTORC2... However, rapamycin extended lifespan despite these metabolic effects." — Lamming DW, Ye L, Katajisto P, et al. Science, 2012

The half-life of rapamycin is ~62 hours, so a weekly dose allows three to four half-lives of washout before the next hit. That window is long enough for mTORC2 to fully reconstitute, which is why weekly protocols deliver the mTORC1-driven lifespan signal without the metabolic baggage. If there is one thing to remember about dosing cadence, it is this: weekly preserves mTORC2; daily destroys it.

Immune Rejuvenation#

Low-dose, intermittent mTOR inhibition reverses several hallmarks of immune aging. It reduces the fraction of exhausted PD-1⁺ T cells, restores naïve T-cell output, and improves hematopoietic stem cell function. In humans, the practical readout is a meaningful improvement in vaccine response in older adults.

"TORC1 inhibition with RAD001 improved the response to influenza vaccination by 20% compared with placebo, suggesting that mTOR inhibition enhances immune function in elderly subjects." — Mannick JB, Del Giudice G, Lattanzi M, et al. Science Translational Medicine, 2014

This is why a 6-week pulse timed before flu season or international travel is a coherent, evidence-backed use case — not just longevity theater.

Metabolic Trade-offs — Lipids and Glucose#

Even at weekly doses, a subset of users see a modest rise in LDL and triglycerides, and transient glucose intolerance on the day or two following the dose. The lipid effect traces to mTORC1's role in SREBP-mediated lipogenesis and hepatic lipid clearance; the glucose effect is partly residual mTORC2 dampening and partly a fasting-like shift in substrate preference.

"Prolonged rapamycin administration resulted in marked hyperlipidemia and impaired glucose tolerance, indicating that chronic mTOR inhibition may have negative metabolic consequences." — Houde VP, Brûlé S, Festuccia WT, et al. Diabetes, 2010

Practically: track lipids and HbA1c at baseline, 3 months, and annually. If LDL drifts, berberine or a low-dose statin resolves it without pulling rapamycin. If fasting glucose creeps up, extending the dosing interval from 7 to 10–14 days usually fixes it — and the mouse lifespan data suggests you lose little by doing so.

Common (most users)#

• Aphthous stomatitis (mouth ulcers) — the single most common complaint at weekly longevity doses. Usually 1–2 small ulcers appearing 3–5 days post-dose. Mitigate with L-lysine 1–3 g/day the day of and day after dosing, vitamin B12 lozenges, and good oral hygiene. If ulcers persist, drop one dose tier or extend the interval to every 10 days.
• Mild GI disturbance — loose stools or mild nausea in the 24 h after dosing. Take with a consistent fatty meal; don't fast around the dose.
• Transient acne-like rash — usually on the chest or back, self-resolves. Standard skincare (adapalene, benzoyl peroxide) is fine to stack.
• Blunted training response if mis-timed — this isn't a "side effect" in the classic sense, but dosing within 24 h of a heavy session will noticeably flatten pumps and soreness-recovery. Schedule the dose on a rest day, ideally 48–72 h out from the next heavy lift.

Uncommon (dose-dependent or individual)#

• Elevated LDL and triglycerides — the classic rapamycin lipid signature. At weekly 5–8 mg most users see modest bumps; a subset sees meaningful rises.

  "Prolonged rapamycin administration resulted in marked hyperlipidemia and impaired glucose tolerance, indicating that chronic mTOR inhibition may have negative metabolic consequences." — Houde et al., Diabetes 2010

  Check a lipid panel at baseline, 3 months, then annually. If LDL jumps >30% or TG cross 200, pair with berberine, bergamot, or a low-dose statin — or drop a tier.

• Impaired fasting glucose / mildly elevated HbA1c — mostly a concern with daily dosing, but some weekly users see it too. Track fasting glucose, fasting insulin, HbA1c at the same cadence as lipids. Blagosklonny's argument is that weekly-dose glucose intolerance mimics fasting-induced insulin resistance rather than pathologic diabetes, but if HbA1c creeps past 5.7 on protocol, extend dosing interval or add metformin.

• Mild cytopenias — small drops in platelets, WBC, or hemoglobin. Picked up on CBC; usually clinically silent. If platelets drop below 150k or WBC below 4.0, hold and recheck in 2 weeks.

• Impaired wound healing — relevant if you're getting tattoos, dental work, or any procedure. Hold dosing for 2 weeks around the event.

• Edema (peripheral) — more common in transplant dosing, occasionally reported at weekly doses. Usually resolves with dose reduction.

Rare but serious#

• Non-infectious pneumonitis — rare at weekly low doses, well-documented at daily transplant doses. Warning signs: persistent dry cough, shortness of breath on exertion, low-grade fever with no infection. Stop dosing and get a chest workup.

• Significant immunosuppression during active infection — rapamycin modulates T-cell function, and the immune-rejuvenation effect Mannick demonstrated is a double-edged sword if dosing occurs during an active infection rather than before a vaccine challenge.

  "TORC1 inhibition with RAD001 improved the response to influenza vaccination by 20% compared with placebo, suggesting that mTOR inhibition enhances immune function in elderly subjects." — Mannick et al., Science Translational Medicine 2014

  Hold dosing during any acute illness until fully recovered.

• Interstitial nephritis, severe hyperlipidemia, severe thrombocytopenia — essentially only seen at daily transplant-grade troughs. Not a realistic concern at weekly 6–8 mg, but the reason why bloodwork matters.

• mTORC2 disruption with chronic daily dosing — the mechanism behind rapamycin's diabetogenic profile, and the reason the community dose weekly.

  "Chronic rapamycin treatment impaired glucose tolerance and insulin sensitivity through disruption of mTORC2… However, rapamycin extended lifespan despite these metabolic effects." — Lamming et al., Science 2012

  If protocols drift into daily or every-other-day dosing, the transplant side-effect profile begins to emerge. Avoid this.

Hard contraindications#

• Active infection — do not dose through a cold, flu, COVID, or any febrile illness. Wait until fully recovered.
• Pending major surgery — hold for at least 2 weeks pre-op through full wound closure. Impaired healing is well-documented.
• Pregnancy or active attempts to conceive (either partner) — rapamycin is Category C and affects sperm parameters. Discontinue ≥3 months before trying to conceive.
• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nefazodone) and strong inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) — these swing exposure wildly. Avoid the combination or do not dose rapamycin until the interacting drug is cleared.
• Grapefruit juice in unpredictable quantities — same CYP3A4 pathway. Either eliminate it entirely or keep intake rigidly consistent.
• Live-attenuated vaccines within the dosing window — space ≥2 weeks. The Mannick protocol deliberately washes out before vaccination; that's different from dosing during an active immune response.
• Uncontrolled hyperlipidemia or uncontrolled diabetes — stabilize first, then start low and monitor. Do not layer rapamycin onto a metabolic panel that's already off the rails.

Gender, fertility, and PCT considerations#

No sex-based dose adjustment is needed — the PEARL trial actually found the strongest lean-mass signal in post-menopausal women at 10 mg compounded weekly.

"Weekly, compounded rapamycin at 5 and 10 mg improved lean mass in postmenopausal women with minimal side effects, establishing key dose-efficacy and safety data for intermittent protocols." — Zalzala et al., Aging 2025

Women: safe on weekly protocols; avoid during pregnancy or active conception attempts. Not virilizing, not hormonal.

Men planning conception: rapamycin transiently affects sperm parameters. Discontinue at least 3 months before trying to conceive and reassess with a semen analysis if in doubt.

PCT: none required. Rapamycin is not hormonal, does not suppress the HPTA, and does not need ancillaries. It stacks cleanly on either side of an AAS cycle — many experienced users run a rapa pulse in between blasts specifically to push autophagy during the off-phase.